Genetic and metabolic investigations for individuals with neurodevelopmental disorders: A survey of Canadian geneticists' practices
- 15 March 2021
- journal article
- research article
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 185 (6) , 1757-1766
Abstract
Neurodevelopmental disorders (NDDs) are genetically heterogeneous. There are many possible etiological investigations for NDDs, and a lack of clear and current guidelines for such testing. Here we characterize the practices of genetic and metabolic physicians in Canada as it pertains to etiological investigation of patients with NDDs, by means of an online questionnaire. The survey response rate was 30% (n = 46). The most commonly ordered first‐line tests for patients with non‐syndromic NDDs are chromosomal microarray (98%) and Fragile X testing (85%). The most commonly ordered second‐line test for non‐syndromic NDDs is a multi‐gene panel (78%) or exome sequencing (29%). Biochemical screening is ordered as a first line test by 33% of respondents, second line by 31%, and rarely or never by 36% of respondents. Those respondents with metabolics fellowship training were more likely to order biochemical screening than those without. The number of years of clinical experience generally did not affect the types of tests ordered. For patients with NDDs, test‐ordering practice among Canadian clinical geneticists is highly variable, in particular with respect to biochemical screening and use of next‐generation sequencing technologies. Evidence‐based guidelines should be developed to facilitate best practices in Canada.Keywords
This publication has 28 references indexed in Scilit:
- Re-evaluating the first-tier status of fragile X testing in neurodevelopmental disordersGenetics in Medicine, 2020
- Methodological quality of clinical practice guidelines for genetic testing in childrenMedicine, 2019
- Evaluation of the child with global developmental delay and intellectual disabilityPaediatrics & Child Health, 2018
- Diagnostic value of partial exome sequencing in developmental disordersPLOS ONE, 2018
- Fragile X testing as a second-tier testGenetics in Medicine, 2017
- Clinical Performance of an Ultrahigh Resolution Chromosomal Microarray Optimized for Neurodevelopmental DisordersBioMed Research International, 2016
- Exploring physician specialist response rates to web-based surveysBMC Medical Research Methodology, 2015
- Confirmation of chromosomal microarray as a first-tier clinical diagnostic test for individuals with developmental delay, intellectual disability, autism spectrum disorders and dysmorphic featuresEuropean Journal of Paediatric Neurology, 2013
- Evidence Report: Genetic and metabolic testing on children with global developmental delay [RETIRED]Neurology, 2011
- Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics supportJournal of Biomedical Informatics, 2009